Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 9c, beats revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RVMD Hot Sheet
Join SI Premium – FREE
Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.92), $0.09 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.82 million versus the consensus estimate of $928.57 thousand.
For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
